MedTrace Logo

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-04-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol, Actigall).

Conditions

  • Primary Biliary Cirrhosis

Interventions

BIOLOGICAL

abatacept

125 mg subcutaneously each week for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Christopher L Bowlus, MD · University of California, Davis

  • M. Eric Gershwin, MD · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078882 on ClinicalTrials.gov